Global Optic Neuropathy (Ophthalmology) Drugs In Development 2021 Market Report – Featuring Antoxis, Astellas Pharma and…

Global Optic Neuropathy (Ophthalmology) Drugs In Development 2021 Market Report – Featuring Antoxis, Astellas Pharma and…

[ad_1]

DUBLIN–()–The “Optic Neuropathy (Ophthalmology) – Drugs In Development, 2021” report has been added to ResearchAndMarkets.com’s offering.

This report provides an overview of the Optic Neuropathy (Ophthalmology) pipeline landscape.

Optic neuropathy is an inherited form of vision loss. Symptoms include eye pain or discomfort, numbness, tingling and clouding of vision. Predisposing factors include age, tobacco smoke, alcohol, cancer treating drugs, stress related chemicals, some antibiotics and cyanogens.

Companies Mentioned

  • Antoxis Ltd
  • Astellas Pharma Inc
  • Biozeus Pharmaceutical SA
  • jCyte Inc
  • Neurizon Pharma GBR
  • PharmatrophiX Inc
  • Quark Pharmaceuticals Inc
  • Regeneron Pharmaceuticals Inc

Report Highlights

The report provides comprehensive information on the therapeutics under development for Optic Neuropathy (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Optic Neuropathy (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Optic Neuropathy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Preclinical and Discovery stages are 1, 1, 6 and 1 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 1 and 2 molecules, respectively.

Optic Neuropathy (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Optic Neuropathy (Ophthalmology).
  • The pipeline guide reviews pipeline therapeutics for Optic Neuropathy (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Optic Neuropathy (Ophthalmology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Optic Neuropathy (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Optic Neuropathy (Ophthalmology)

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Optic Neuropathy (Ophthalmology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Optic Neuropathy (Ophthalmology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Key Topics Covered:

Introduction

Optic Neuropathy – Overview

  • Optic Neuropathy – Therapeutics Development

Pipeline Overview

  • Pipeline by Companies
  • Pipeline by Universities/Institutes
  • Products under Development by Companies
  • Products under Development by Universities/Institutes

Optic Neuropathy – Therapeutics Assessment

  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type

Optic Neuropathy – Companies Involved in Therapeutics Development

  • Antoxis Ltd
  • Astellas Pharma Inc
  • Biozeus Pharmaceutical SA
  • jCyte Inc
  • Neurizon Pharma GBR
  • PharmatrophiX Inc
  • Quark Pharmaceuticals Inc
  • Regeneron Pharmaceuticals Inc

Optic Neuropathy – Drug Profiles

Optic Neuropathy – Dormant Projects

Optic Neuropathy – Discontinued Products

Optic Neuropathy – Product Development Milestones

Featured News & Press Releases

Appendix

For more information about this report visit https://www.researchandmarkets.com/r/r49qo0

[ad_2]

Source link

Robert Swift

Leave a Reply

Your email address will not be published.